Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.45 |
| ▸ | ESR1 | P03372 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28482640 | 0.94 | FAAH (0.54) | FAAHESR1NAAATSHR | |
| SCHEMBL28259907 | 0.93 | FAAH (0.40) | FAAHESR1HTTRECQLALDH1A1 | |
| SCHEMBL411643 | 0.86 | GAA (0.44) | HTTTDP1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL30167907 | 0.81 | DPP4 (0.41) | ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL725284 | 0.81 | DPP4 (0.41) | ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL28259908 | 0.76 | ALDH1A1 (0.35) | HTTRECQLALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL28301761 | 0.76 | MTNR1A (0.48) | — | |
| SCHEMBL28667462 | 0.76 | TSHR (0.39) | ALDH1A1TSHRSMN1; SMN2KMT2A | |
| SCHEMBL18752139 | 0.75 | ATM (0.41) | ESR1TDP1L3MBTL1TSHRSMN1; SMN2 | |
| SCHEMBL18752140 | 0.75 | DPP4 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305822-A1 | METHOD FOR PREPARING SITAGLIPTIN INTERMEDIATE VIA ASYMMETRICAL REDUCTION METHOD | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2017-10-26 | — | — | US | disclosed |
| EP-3156391-A1 | METHOD FOR PREPARING SITAGLIPTIN INTERMEDIATE VIA ASYMMETRICAL REDUCTION METHOD | Zhejiang Huahai Pharmaceutical Co., Ltd (CN) | 2017-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305822-A1 | METHOD FOR PREPARING SITAGLIPTIN INTERMEDIATE VIA ASYMMETRICAL REDUCTION METHOD | DPP4, DPP7, SI | FAAH 2979/4885ESR1 1132/4885HTT 3378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.